Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study

To test the prognostic value of emerging biomarkers in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED‐HF) trial.

[1]  J. McMurray,et al.  The incremental prognostic and clinical value of multiple novel biomarkers in heart failure , 2016, European journal of heart failure.

[2]  Christopher J. Rush,et al.  Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. , 2015, JACC. Heart failure.

[3]  S. Hazen,et al.  Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure. , 2015, The American journal of medicine.

[4]  F. Formiga,et al.  Troponin T in acute heart failure: clinical implications and prognosis in the Spanish National Registry on Heart Failure. , 2014, European journal of internal medicine.

[5]  A. Santoro,et al.  Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology , 2014, Clinical chemistry and laboratory medicine.

[6]  Mark Woodward,et al.  Risk prediction in patients with heart failure: a systematic review and analysis. , 2014, JACC. Heart failure.

[7]  M. Cho,et al.  Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). , 2014, The American journal of cardiology.

[8]  Thomas J. Wang,et al.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. , 2014, JACC. Heart failure.

[9]  J. McMurray,et al.  Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure: Results From the CORONA Trial , 2013, Circulation. Heart failure.

[10]  U. Maggiore,et al.  Prealbumin improves death risk prediction of BNP-added Seattle Heart Failure Model: results from a pilot study in elderly chronic heart failure patients. , 2013, International journal of cardiology.

[11]  A. Cohen-Solal,et al.  Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. , 2013, International journal of cardiology.

[12]  R. D. de Boer,et al.  Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. , 2013, The American journal of cardiology.

[13]  Karl Swedberg,et al.  Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.

[14]  Akshay S. Desai,et al.  Treatment of anemia with darbepoetin alfa in systolic heart failure. , 2013, The New England journal of medicine.

[15]  A. Jaffe,et al.  Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. , 2013, The American journal of cardiology.

[16]  P. Ponikowski,et al.  Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) , 2013, European journal of heart failure.

[17]  M. de Antonio,et al.  Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification , 2012, PloS one.

[18]  W. W. Tang,et al.  Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review , 2012, Heart.

[19]  S. Hazen,et al.  Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events , 2012, Circulation. Heart failure.

[20]  S. Manzano-Fernández,et al.  Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. , 2012, American heart journal.

[21]  I. Gustafsson,et al.  Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. , 2012, Journal of cardiac failure.

[22]  P. Ponikowski,et al.  Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study , 2011, Circulation. Heart failure.

[23]  P. Ponikowski,et al.  Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2011, Journal of the American College of Cardiology.

[24]  G. Jakl,et al.  Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure , 2011, European journal of heart failure.

[25]  J. Rehfeld,et al.  Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. , 2011, JAMA.

[26]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[27]  P. Ponikowski,et al.  Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure , 2010, European journal of heart failure.

[28]  J. McMurray,et al.  Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis , 2009, Circulation.

[29]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[30]  M. Nieminen,et al.  Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.

[31]  I. Kubota,et al.  Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. , 2005, Journal of cardiac failure.

[32]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[33]  B. Psaty,et al.  Cystatin-C and mortality in elderly persons with heart failure. , 2005, Journal of the American College of Cardiology.

[34]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016 .